LLY

In April 2026, Eli Lilly's shares jumped nearly 6% following the U.S. FDA approval of orforglipron (Foundayo), its new oral GLP-1 drug for obesity, and strong first-quarter 2026 financial results showing 56% revenue growth and increased full-year revenue guidance. In September 2026, the stock dipped slightly after Phase 2b results for EloraTZP, an experimental weight loss treatment, showed significant weight reduction but also higher discontinuation rates due to side effects, though full cardiovascular results for Foundayo demonstrated it met its safety goal. By October 2026, the stock continued its upward trend, driven by the strong performance of GLP-1 products Mounjaro and Zepbound, which contributed to 48% year-over-year revenue growth in Q2 2026, and the FDA approval of once-weekly insulin Onswik. JPMorgan raised its price target for LLY, citing powerful incretin trends and international obesity demand, with the stock increasing by 41.35% over the last 12 months as of October 10, 2026.